Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA LIPIDS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 MERGER AND ACQUISITION, NORTH AMERICA LIPIDS MARKET
4.4 PATENT ANALYSIS, NORTH AMERICA LIPIDS MARKET
4.5 DRUG TREATMENT RATE BY MATURED MARKETS
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE
4.7 KEY PRICING STRATEGIES
4.8 KEY PATIENT ENROLLMENT STRATEGIES
4.9 PRICE ANALYSIS, NORTH AMERICA LIPIDS MARKET
4.1 NORTH AMERICA LIPIDS MARKET, CLINICAL TRIALS
4.11 NORTH AMERICA LIPIDS MARKET, DISTRIBUTION OF PRODUCTS BY PHASE
4.12 NORTH AMERICA LIPIDS MARKET, PIPELINE ANALYSIS
4.13 PHASE I CANDIDATES
4.14 PHASE I/II CANDIDATES
4.15 PHASE II CANDIDATES
4.16 PHASE III CANDIDATES
5 NORTH AMERICA LIPIDS MARKET, REGULATORY FRAMEWORK
5.1 REGULATION IN THE U.S.:
5.2 REGULATION IN EUROPE:
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN THE PREVALENCE OF CHRONIC DISEASES
6.1.2 RISE IN DEMAND FOR LIPIDS IN FOOD AND BEVERAGE AS WELL AS THE COSMETIC INDUSTRY
6.1.3 INCREASE IN DRUG DEVELOPMENT
6.2 RESTRAINTS
6.2.1 HIGH COST OF LIPID SYNTHESIS AND INCREASING COST OF RAW MATERIALS
6.2.2 STRICT GOVERNMENT REGULATIONS
6.3 OPPORTUNITIES
6.3.1 RISE IN HEALTHCARE EXPENDITURE
6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.4 CHALLENGES
6.4.1 DIFFERENT MANUFACTURING CHALLENGES FOR LIPID NANOPARTICLE PRODUCTION
6.4.2 LACK OF HEALTHCARE FACILITIES IN EMERGING ECONOMIES
7 NORTH AMERICA LIPIDS MARKET, BY TYPE
7.1 OVERVIEW
7.2 NATURAL LIPID
7.2.1 UNSATURATED PHOSPHOLIPID
7.2.2 HYDROGENATED PHOSPHOLIPID
7.2.3 SPHINGOMYELIN
7.2.4 GLYCEROLPHOSPHOCHOLINE
7.3 SYNTHETIC LIPID
7.3.1 PEGYLATED PHOSPHOLIPIDS
7.3.2 PHOSPHATIDYLSERINE
7.3.3 PHOSPHATIDYGLYCEROLS
7.3.4 PHOSPHATIDYLETHANOLAMINE
7.3.5 PHOSPHATIDYLCHOLINE
7.3.6 PHOSPHATIDIC ACIDS
8 NORTH AMERICA LIPIDS MARKET, BY LIPID SYSTEMS
8.1 OVERVIEW
8.2 BIOACTIVE LIPIDS
8.2.1 PLANT LIPIDS
8.2.2 LIPID ACTIVATORS
8.2.3 LIPID INHIBITORS
8.2.4 AGONISTS
8.2.5 BIOACTIVE CERAMIDES
8.2.6 ACYL CARNITINE LIPIDS
8.2.7 ENDOCANNABINOIDS
8.2.8 LIPO-NUCLEOTIDES
8.2.9 LYSYL-PHOSPHATIDYLGLYCEROL
8.2.10 DIACYLGLYCEROL PYROPHOSPHATE (DGPP)
8.3 POLYMERIZABLE LIPIDS
8.3.1 FUNCTIONAL PEG LIPIDS
8.3.2 MPEG STEROLS
8.3.3 MPEG CERAMIDES
8.3.4 MPEG PHOSPHOLIPIDS
8.3.5 MPEG GLYCERIDES
8.4 FLUORESCENT LIPIDS
8.4.1 FLUORESCENT SPHINGOLIPIDS
8.4.2 FLUORESCENT GLYCEROLIPIDS
8.4.3 FLUORESCENT PEG LIPIDS
8.4.4 FLUORESCENT PHOSPHOLIPIDS
8.4.5 FLUORESCENT STEROLS
8.4.6 OTHERS
8.5 BACTERIAL LIPIDS
8.5.1 MYCOLIC LIPIDS
8.5.2 N-ACYLHOMOSERINE LIPIDS
8.5.3 BRANCHED LIPIDS
8.5.4 CYCLOPROPYL LIPIDS
8.6 NEUTRAL LIPIDS
8.6.1 PRENOLS
8.6.2 VERY LONG CHAIN FATTY ACIDS
8.6.3 GLYCERIDES
8.6.4 EICSANOIDS
8.6.5 OXYGENATED FATTY ACIDS
8.6.6 GLYCOSYLATED DIACYL GLYCEROLS
8.6.7 PROSTAGLANDINS
8.7 HEADGROUP MODIFIED LIPIDS
8.7.1 FUNCTIONAL LIPIDS
8.7.2 ANTIGENIC LIPIDS
8.7.3 GLYCOSYLATED LIPIDS
8.7.4 CHELATORS
8.7.5 ADHESIVE LIPIDS
8.7.6 SNAP-TAG REACTING LIPIDS
8.7.7 ALKYL PHOSPHATES
8.8 OTHERS
9 NORTH AMERICA LIPIDS MARKET, BY DELIVERY SYSTEMS
9.1 OVERVIEW
9.2 LIPOSOMES
9.2.1 LIPOSOMES FOR DNA/RNA
9.2.1.1 DOTAP LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.2 DDAB LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.3 GL-67 LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.4 DC-CHOLESTEROL LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.5 DOTMA LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.6 DODAP LIPOSOMES FOR DNA/RNA DELIVERY
9.2.2 REACTIVE LIPOSOMES
9.2.2.1 SUCCINYL LIPOSOMES
9.2.2.2 DBCO LIPOSOMES
9.2.2.3 BIOTINYLATED LIPOSOMES
9.2.2.4 CARBOXYLIC ACID LIPOSOMES
9.2.2.5 AMINE LIPOSOMES
9.2.2.6 CYANUR LIPOSOMES
9.2.2.7 AZIDE LIPOSOMES
9.2.2.8 FOLATE LIPOSOMES
9.2.2.9 DODECANYL LIPOSOMES
9.2.2.10 NI REACTIVE LIPOSOMES
9.2.2.11 PDP LIPOSOMES
9.2.2.12 GLUTARYL LIPOSOMES
9.2.2.13 OTHERS
9.2.3 DRUG LOADED LIPOSOMES
9.2.4 PLAIN LIPOSOMES
9.2.4.1 CARDIOLIPIN LIPIDS LIPOSOMES
9.2.4.2 DOTAP LIPOSOMES
9.2.4.3 PHOSPHATIDYLSERINE LIPOSOMES
9.2.4.4 PHOSPHATIDYLCHOLINE LIPOSOMES
9.2.4.5 PHOSPHATIDYL GLYCEROL LIPOSOMES
9.2.4.6 OTHERS
9.3 SOLID LIPID NANOPARTICLES
9.4 NANOSTRUCTURES LIPID CARRIER
9.5 TRANSFEROSOMES
9.6 NIOSOMES
9.7 OTHERS
10 NORTH AMERICA LIPIDS MARKET, BY SOURCE
10.1 OVERVIEW
10.2 PURIFIED FATTY ACIDS
10.3 PURIFIED OILS
10.4 EGG YOLK
10.5 SOYABEAN
10.6 NON-GMO SOYABEAN
10.7 OTHERS
11 NORTH AMERICA LIPIDS MARKET, BY END USER
11.1 OVERVIEW
11.2 PHARMACEUTICAL INDUSTRIES
11.3 BIOTECHNOLOGY INDUSTRIES
11.4 COSMETIC INDUSTRIES
11.5 ACADEMIC AND RESEARCH INSTITUTES
11.6 OTHERS
12 NORTH AMERICA LIPIDS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 OTHERS
13 NORTH AMERICA LIPIDS MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
14 NORTH AMERICA LIPIDS MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 BIONTECH SE.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 MODERNA, INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 PFIZER INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 CARGILL, INCORPORATED.
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 KERRY.
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 ABITEC
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 ADMSIO
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENTS
16.8 ALNYLAM PHARMACEUTICALS, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 BASF SE
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 CAYMAN CHEMICAL
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENTS
16.11 CD BIOPARTCLES.
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENTS
16.12 CHEMI S.P.A.
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENTS
16.13 CORDENPHARMA INTERNATIONAL
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 CRODA INTERNATIONAL PLC.
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENTS
16.15 CURIA NORTH AMERICA, INC.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 DSM
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENTS
16.17 EVONIK INDUSTRIES AG
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 GATTEFOSSÉ
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENTS
16.19 LIPOID GMBH
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 MATREYA, LLC
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
16.21 MERCK KGAA
16.21.1 COMPANY SNAPSHOT
16.21.2 PRODUCT PORTFOLIO
16.21.3 RECENT DEVELOPMENTS
16.22 NOF EUROPE GMBH
16.22.1 COMPANY SNAPSHOT
16.22.2 PRODUCT PORTFOLIO
16.22.3 RECENT DEVELOPMENTS
16.23 STEPAN COMPANY
16.23.1 COMPANY SNAPSHOT
16.23.2 PRODUCT PORTFOLIO
16.23.3 RECENT DEVELOPMENTS
16.24 TOKYO CHEMICAL INDUSTRY CO., LTD.
16.24.1 COMPANY SNAPSHOT
16.24.2 PRODUCT PORTFOLIO
16.24.3 RECENT DEVELOPMENTS
16.25 VAV LIFE SCIENCES PVT LTD
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 ASP FOR MAJOR DRUGS IN LIPIDS MARKET (PRICE IN USD)
TABLE 2 LIPID BASED NANO PARTICLE FOR COVID-19 VACCINES
TABLE 3 LIPID BASED NANO PARTICLE FOR CANCER VACCINES
TABLE 4 RNA ENCAPSULATED LIPID NANOPARTICLES
TABLE 5 LIPOSOMAL FORMULATIONS
TABLE 6 LIPID BASED NANO PARTICLE FOR COVID VACCINES
TABLE 7 LIPOSOMAL FORMULATION
TABLE 8 LIPID BASED NANO PARTICLE FOR CANCER VACCINES
TABLE 9 RNA ENCAPSULATED LIPID NANOPARTICLES
TABLE 10 LIPOSOME FORMULATIONS
TABLE 11 LIPID BASED NANO PARTICLE FOR COVID VACCINES
TABLE 12 LIPID BASED NANO PARTICLE FOR CANCER VACCINES
TABLE 13 LIPOSOMAL FORMULATION
TABLE 14 NORTH AMERICA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA NATURAL LIPID IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA SYNTHETIC LIPID IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA BACTERIAL LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA NEUTRAL LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA LIPOSOMES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA SOLID LIPID NANOPARTICLES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA NANOSTRUCTURES LIPID CARRIER IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA TRANSFEROSOMES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA NIOSOMES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA PURIFIED FATTY ACIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA PURIFIED OILS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA EGG YOLK IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA SOYABEAN IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA NON-GMO SOYABEAN IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA PHARMACEUTICAL INDUSTRIES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA BIOTECHNOLOGY INDUSTRIES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA COSMETIC INDUSTRIES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA DIRECT TENDER IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA RETAIL SALES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 NORTH AMERICA LIPIDS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 62 NORTH AMERICA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 63 NORTH AMERICA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 64 NORTH AMERICA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 65 NORTH AMERICA LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 67 NORTH AMERICA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 68 NORTH AMERICA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 69 NORTH AMERICA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 70 NORTH AMERICA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 71 NORTH AMERICA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 72 NORTH AMERICA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 73 NORTH AMERICA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 74 NORTH AMERICA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 75 NORTH AMERICA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 76 NORTH AMERICA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 77 NORTH AMERICA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 78 NORTH AMERICA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 79 NORTH AMERICA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 80 U.S. LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 81 U.S. NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 82 U.S. SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 83 U.S. LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 84 U.S. NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 85 U.S. BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 86 U.S. FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 87 U.S. BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 88 U.S. POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 89 U.S. HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 90 U.S. LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 91 U.S. LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 92 U.S. LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 93 U.S. REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 94 U.S. PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 95 U.S. LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 96 U.S. LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 97 U.S. LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 98 CANADA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 99 CANADA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 100 CANADA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 101 CANADA LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 102 CANADA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 103 CANADA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 104 CANADA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 105 CANADA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 106 CANADA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 107 CANADA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 108 CANADA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 109 CANADA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 110 CANADA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 111 CANADA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 112 CANADA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 113 CANADA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 114 CANADA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 115 CANADA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 116 MEXICO LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 117 MEXICO NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 118 MEXICO SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 119 MEXICO LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 120 MEXICO NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 121 MEXICO BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 122 MEXICO FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 123 MEXICO BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 124 MEXICO POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 125 MEXICO HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 126 MEXICO LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 127 MEXICO LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 128 MEXICO LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 129 MEXICO REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 130 MEXICO PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 131 MEXICO LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 132 MEXICO LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 133 MEXICO LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA LIPIDS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA LIPIDS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA LIPIDS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA LIPIDS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA LIPIDS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA LIPIDS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA LIPIDS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA LIPIDS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA LIPIDS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA LIPIDS MARKET: SEGMENTATION
FIGURE 11 THE GROWING PRVALENCE OF CHRONIC DISEASES AND RISING DEMAND FOR LIPIDS IN VARIOUS INDUSTRIES ARE EXPECTED TO DRIVE THE NORTH AMERICA LIPIDS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 TESTING SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LIPIDS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA LIPIDS MARKET
FIGURE 14 NORTH AMERICA LIPIDS MARKET: BY TYPE, 2022
FIGURE 15 NORTH AMERICA LIPIDS MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA LIPIDS MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA LIPIDS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA LIPIDS MARKET: BY LIPID SYSTEMS, 2022
FIGURE 19 NORTH AMERICA LIPIDS MARKET: BY LIPID SYSTEMS, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA LIPIDS MARKET: BY LIPID SYSTEMS, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA LIPIDS MARKET: BY LIPID SYSTEMS, LIFELINE CURVE
FIGURE 22 NORTH AMERICA LIPIDS MARKET: BY DELIVERY SYSTEMS, 2022
FIGURE 23 NORTH AMERICA LIPIDS MARKET: BY DELIVERY SYSTEMS, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA LIPIDS MARKET: BY DELIVERY SYSTEMS, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA LIPIDS MARKET: BY DELIVERY SYSTEMS, LIFELINE CURVE
FIGURE 26 NORTH AMERICA LIPIDS MARKET: BY SOURCE, 2022
FIGURE 27 NORTH AMERICA LIPIDS MARKET: BY SOURCE, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA LIPIDS MARKET: BY SOURCE, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA LIPIDS MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 30 NORTH AMERICA LIPIDS MARKET: BY END USER, 2022
FIGURE 31 NORTH AMERICA LIPIDS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 32 NORTH AMERICA LIPIDS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 33 NORTH AMERICA LIPIDS MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 NORTH AMERICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 35 NORTH AMERICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 36 NORTH AMERICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 37 NORTH AMERICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 NORTH AMERICA LIPIDS MARKET: SNAPSHOT (2022)
FIGURE 39 NORTH AMERICA LIPIDS MARKET: BY COUNTRY (2022)
FIGURE 40 NORTH AMERICA LIPIDS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 NORTH AMERICA LIPIDS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 NORTH AMERICA LIPIDS MARKET: BY TYPE (2023 & 2030)
FIGURE 43 NORTH AMERICA LIPIDS MARKET: COMPANY SHARE 2022 (%)
